Increasing occurrence of antimicrobial resistance in both typhoidal and nontyphoidal salmonellae is a major public health problem. Recent studies documenting the occurrence and types of resistance, with particular reference to quinolones and extended spectrum cephalosporins, and new approaches to treatment are reviewed.
Introduction
Infections with Salmonella are an important public health problem worldwide. Enteric fever, most commonly caused by S. enterica serovars Typhi (S. Typhi) and Paratyphi A, both exclusively human pathogens, has been estimated to cause 27 million cases each year with more than 200 000 deaths [1] . There are many data gaps in that estimate, and a review of data from Africa suggests that enteric fever may be much less common there than currently assumed [2 ] . The lack of competent microbiology facilities with the ability to culture blood in suspected enteric fever cases, coupled with the resulting reliance on the Widal test, leads to over-diagnosis and inappropriate treatment in many areas of Africa and Asia.
Infection by the nontyphoidal Salmonella (NTS) serovars is estimated to cause an even larger burden of disease worldwide and in developed countries it is commonly considered to be acquired from animals through the food chain [3] . Although NTS usually causes self-limiting diarrhoea, invasive infection with bacteraemia and focal infections may occur. Invasive NTS infections are more common in young children, the elderly and the immunocompromised. Particular serovars such as Choleraesuis, Dublin and Virchow have an increased propensity to cause invasive infections [4] . In the countries of sub-Saharan Africa, invasive NTS infections are a particular problem in infants, young children and in young adults with HIV infection [5 ] . In patients with HIV infection, invasive salmonellosis may be recurrent [6] .
Salmonella diarrhoea is generally self-limiting, and antimicrobials are usually not required for treatment. They are critical, however, to the successful outcome of invasive and focal NTS infections and enteric fever. Resistance to the older antimicrobials, chloramphenicol, ampicillin and trimethoprim-sulphamethoxazole (co-trimoxazole) has been present for many years. In the face of such multidrug resistance, fluoroquinolones have been commonly used. Treatment failures have been described in strains displaying decreased ciprofloxacin susceptibility (DCS) [ciprofloxacin minimum inhibitory concentration (MIC) 0.125-1.0 mg/l] [7] . Nalidixic acid resistance has been a reliable indicator of such isolates, which have become common in many areas, but this is no longer the case. More recently, full resistance to the fluoroquinlones and also to the extended spectrum cephalosporins has been reported. The current situation concerning antimicrobial resistance in Salmonella is the subject of this review.
Surveillance of resistance in typhoidal salmonellae
A large burden of disease study in five Asian countries has been co-ordinated by the International Vaccine Institute (IVI) to inform policy makers concerning the introduction of preventive interventions against typhoid fever such as vaccination [8 ] . This study is part of the Diseases of the Most Impoverished (DOMI) Programme. The observed rates of typhoid were variable between different sites and in different age groups. Generally, the highest rates were seen in the 5-15 years age range and varied from 493.5 and 412.9 per 100 000 population in Kolkata, India and Karachi, Pakistan; 180.3 per 100 000 in Jakarta, Indonesia; and 29.3 and 24.2 per 100 000 in Hechi, China and Hue, Viet Nam, respectively. In Pakistan, India and Indonesia, very high rates were also seen in children aged 2-4 years. Overall, only 9% of these patients, all blood-culture positive, required hospital admission. The strains tested from Indonesia and China showed no resistance to the antimicrobials commonly used for treatment. Multidrug resistance [resistance to ampicillin, trimethoprim-sulphamethoxazole (co-trimoxazole) and chloramphenicol)] was found in 7% of isolates from India, 22% from Viet Nam and 65% from Pakistan (Table 1) [9-11,12 ,13-16] . Furthermore, nalidixic acid resistance occurred in 44% of isolates from Viet Nam, 57% in India and 59% in Pakistan. The particular significance of these data is that the bacteria were isolated from patients in the community and thus avoided the potential bias inherent in studying isolates from the subset of patients admitted to hospital. Another study across six Asian countries used hospital-based isolates to study variations in resistance rates [13] . Two hundred and four S. Typhi isolates were collected in 2002-2004. The proportion of multidrugresistant (MDR) isolates ranged from 74% in Viet Nam to 0% in The Phillipines and isolates with DCS from 90% of isolates from Viet Nam to 18% from Sri Lanka (Table 1) .
Antimicrobial-resistant enteric fever has been a particular problem in Viet Nam since the early 1990s. Chau et al. [9] reviewed the changes in resistance occurring in the south of the country between 1993 and 2005. An epidemic of MDR typhoid in the early 1990s was followed by an epidemic of nalidixic acid-resistant (Na R ) disease in the second half. In 2005, the multidrug resistance rate was 50% and nalidixic acid resistance rate 97%. The predominant mutation causing nalidixic acid resistance in the quinolone-resistance determining region (QRDR) of gyr A gene of isolates from southern Viet Nam was a Ser83Phe substitution. Comparison of these results with isolates from Bangladesh, China, India, Indonesia, Laos, Nepal, Pakistan and central Viet Nam showed multidrug resistance rates varying from 16 to 37% and nalidixic acid resistance rates between 5 and 55% (Table 1 ). In a further study of isolates from various locations in Viet Nam over a similar time period, single nucleotide polymorphism (SNP) analysis demonstrated that all Na R isolates belonged to a single clone, haplotype H58 [17] . This haplotype had been shown in a previous study to be particularly associated with the epidemic of nalidixic acid resistance in Asia [18] . Microevolution of the strain was demonstrated by pulse-field gel electrophoresis (PFGE), with a predominant profile X3-S6 in 1996-2002 replaced by a different profile X1-S1 after 2002. The principal mutation in the QRDR of the gyrA gene was again confirmed as a replacement of Ser83 by Phe. These results point to the clonal expansion and spread of particular quinolone-resistant strains over several years.
In a longitudinal study in Kathmandu, Nepal, between 1993 and 2003, the blood-culture isolates from outpatients and inpatients were studied [14] . Salmonella accounted for 9124 (74.5%) of the positive blood cultures with 70.7% of those serovar Typhi and 29.3% serovar Paratyphi A. There was a significant increase in S. Paratyphi A as a proportion of the positive cultures from 23% in 1993-1998 to 34% in 1999-2003 (P < 0.001) ( Table 1 ). The occurrence of resistance to chloramphhenicol, ampicillin and co-trimoxazole decreased in Typhi isolates, from 21-49% in 1993-1998 to 12-14% in 1999-2003 and from 5-28% to 2-6% in Paratyphi A isolates. In 1999-2003, 5% of Typhi and 13% of Paratyphi A isolates demonstrated resistance to ciprofloxacin by disc diffusion.
Fully fluoroquinolone-resistant isolates of Typhi and Paratyphi A (MIC > 2.0 mg/l) have been reported from other parts of the Indian subcontinent. In a selection of isolates from blood cultures during 2004 in a hospital in Bangalore, India, nalidixic acid resistance was seen in 17 out of 25 (68%) of Typhi and 21 out of 25 (84%) of Paratyphi A isolates [19] . Five Typhi and six Paratyphi A isolates were fully resistant to ciprofloxacin. In Kolkata, India, two fluoroquinolone-resistant S. Typhi were isolated, with MICs of ciprofloxacin and ofloxacin of 16 mg/l [20] . Analysis of the strains showed two mutations in gyrA (Ser83Phe and Asp87Gly) and a single mutation in the parC region (Ser87Ile). The two strains were isolated from members of the same family and had identical PFGE profiles. The isolates were resistant to co-trimoxazole but susceptible to chloramphenicol and ampicillin. In New Delhi, India, Raveendran et al. [12 ] . Over the period of study, the proportion of isolates resistant to any antimicrobial increased from 57 to 66% (P < 0.001). In contrast, the proportion showing multidrug resistance (defined as resistance to four or more antimicrobials) declined from 18 to 15%. In 2004, resistances to sulphonamides (28%), tetracyclines (20%), ampicillin (20%), streptomycin (18%) and chloramphenicol (8%) were the most common phenotypes. Of note was a significant increase in nalidixic acid resistance from 14% in 2000 to 20% in 2004 (P < 0.001) and a decline in cefotaxime resistance from 0.7 to 0.2% (P < 0.001).
In this study, nearly 80% of the serovars were Enteritidis, Typhimurium or Virchow. In the Enteritidis isolates, resistance to at least one antimicrobial doubled from 19 to 39%. Furthermore, nalidixic acid resistance increased from 10 to 26% and ciprofloxacin resistance from 0.2 to 0.9% (P < 0.001) ( Table 2 [ 21 ,22,23,24 ] ). There is some evidence from England and Wales that this increase was particularly found in S. Enteritidis phage type (PT)1 and associated with travel to southern Europe and eating eggs imported from certain countries in this region. A total of 76% of Typhimurium and 73% of Virchow isolates were resistant to at least one antimicrobial, with little change in the incidence of resistance in Typhimurium but an increase in the Virchow rates over the study period. For Typhimurium, the proportion of Na R isolates varied between 6 and 7%. For Virchow, nalidixic acid resistance was 59%, that for ciprofloxacin and cefotaxime were 4 and 1%, respectively, in 2004. This is of concern as Virchow has a known predilection for extraintestinal spread. In other studies, drug-resistant Virchow isolates have been linked to poultry and poultry products in France and Thailand.
A number of studies have reported data from other regions in the world. In the Gulf States of Kuwait and the United Arab Emirates (UAE), a study of 369 NTS isolates showed multidrug resistance rates of 9.8 and 4.1%, respectively [22] . Resistance rates to individual drugs varied in Kuwait and in the UAE from 26.5 to 17.1% to ampicillin, 26.1 to 8.9% to trimethoprimsulphamethoxazole, 5.6 to 5.7% to chloramphenicol, 14.2 to 7.4% DCS, 1.2 to 0.8% to ciprofloxacin and 1.6 to 1.6% to cefotaxime/ceftriaxone. In a study in Senegal of 249 NTS isolates from 2004 to 2006, 12 (4.8%) were Na R with DCS including 10 strains of serovar Enteritidis, one Chester and one Virchow [23] . Resistance to other commonly used antimicrobials was 10% or less.
The emergence of multidrug resistance in a 7-year review of 4956 episodes of invasive NTS infection in adults and children in Malawi was described by Gordon et al. [25 ] . Three quarters of the isolates were serovar Typhimurium and 21% were Enteritidis. There were sequential epidemic increases in cases caused by S. Enteritidis and the S. Typhimurium temporally associated with the acquisition of multidrug resistance to ampicillin, cotrimoxazole and chloramphenicol. The case fatality rate among children was 22% and that among adults was 20%, though the acquisition of multidrug resistance was not associated with an increase in case fatality rate.
In Siriraj Hospital in Bangkok during 2005, 135 bacteraemic isolates of NTS were studied [24 ] . Salmonella group C was the most common serogroup (47%) followed by group D and then B, and 32% of the patients were HIV seropositive. Resistance rates to ampicillin (57%), chloramphenicol (48%) and trimethoprim-sulphamethoxazole (35%) were high with 30% of isolates MDR. An alarming 17.8% of isolates were resistant to ceftriaxone/cefotaxime and 5.2% were resistant to ciprofloxacin. The proportion of strains with DCS was not determined, and the resistance mechanisms were not further characterized. Full ciprofloxacin resistance has been described in isolates of serovar Typhimurium in China [26] . Faecal isolates from patients in a hospital in Wuhan included 36 out of 44 patients (82%) displaying resistance to at least eight antimicrobials and 31 out of 44 (70%) resistant to ciprofloxacin (MIC 4 mg/l). A total of 21 out of 44 (87.5%) patients were resistant to amoxicillin-clavulanic acid, ampicillin, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulphamethoxazole, streptomycin, trimethoprim-sulphamethoxazole and tetracycline. The ciprofloxacin-resistant isolates had a minimum of three mutations in gyrA and parC and two had an additional mutation in parE, but no gyrB mutations or qnr genes were found. The isolates were susceptible to extended spectrum cephalosporins. Several PFGE patterns were demonstrated.
Plasmid-mediated quinolone and extended spectrum cephalosporin resistance
Although quinolone resistance usually arises due to mutations in the topoisomerase genes (commonly gyrA 534 Gastrointestinal infections DCS, decreased ciprofloxacin susceptibility; ESC, extended spectrum cephalosporin; MIC, minimum inhibitory concentration; Na R , nalidixic acid resistant; ND, not done.
followed by parC), plasmid-mediated resistance is increasingly recognized in Enterobacteriacae. The plasmid genes responsible are qnr, a gene that encodes a protein that protects DNA gyrase from ciprofloxacin, and aac(6')-Ib-cr, an aminoglycoside-modifying enzyme with activity against ciprofloxacin. A concern about the carriage of plasmid-mediated quinolone resistance genes in Salmonella is that the plasmid may also contain an extended spectrum cephalosporin resistance gene, thereby limiting the efficacy of two important antimicrobials used to treat invasive salmonellosis. A number of studies have investigated the incidence and type of these genes in S. enterica.
In one such investigation in the Netherlands, 15 011 Salmonella isolates from humans and various animal sources collected between 1999 and 2006 were studied if they showed the phenotype of DCS (MIC 0.25-1 mg/l) but remained susceptible to nalidixic acid (MIC 8-16 mg/l) [27] . A total of 34 of the 39 (87%) isolates with this phenotype were found to contain a qnr gene, 31 with qnrS1 and two with qnrB5' from human isolates and one qnrB2 from a broiler chicken. No qnrA or aac(6')-Ib-cr genes were detected. The qnr genes were detected in eight different serovars. qnrS1 genes were detected in 25 isolates of S. Corvallis. Corvallis isolates with qnrS1 have also been detected from Denmark and Thailand and strain typing by PFGE showed a high similarity between Thai, Dutch and Danish isolates [28] .
In the UK, Hopkins et al. [29] screened 118 archived S. enterica isolates collected between 1993 and 2005 that were resistant to ciprofloxacin (MIC > 0.125 mg/l) and cefotaxime (>1 mg/l). Six strains [Stanley (two), Virchow (two), Typhimurium (one) and Virginia (one)] were found to contain qnrS1. The qnrS1 gene was found on different plasmid backbones in the different isolates and in one case was co-transferred with a CTX-M Extended Spectrum Beta-Lactamase (ESBL) gene. Five of the isolates were associated with foreign travel to, or food imported from, the Far East. In a further study from October 2006 to April 2007, a further 37 qnrS and two qnrB-containing isolates were identified [30] . The qnrS1 isolates belonged to serovars Typhimurium (21), Virchow (10) and Corvallis (six). The Typhimurium isolates were mainly definitive phage types (DTs)120 or 193. Travel histories and molecular typing suggested links with travel to the Far East in some of the cases. Two isolates also showed resistance to extended spectrum cephalosporins. The same group went on to determine the complete nucleotide sequence of the qnrS1-containing plasmid from S. Typhimurium DT193, TPqnrS-1a [31] . The plasmid was relatively small at 10 066 base pairs, and qnrS1 was the sole resistance gene.
Studies in Europe have shown a low percentage of qnr and extended spectrum cephalosporin resistance genes in salmonellae. In a study of 499 Salmonella isolates in France, only a single isolate was qnrA1 positive [32] . The serovar Concord isolate also carried the ESBL gene bla CTX-M- 15 . In France, serovar Newport isolates with the bla CMY-2 were also reported to cause sporadic cases and outbreaks between 2000 and 2005 [33] . The authors hypothesized these isolates entered France in imported meat as the strain was not found in domestic animals or domestically produced food products. Only two ESBL resistance genes were found in 1708 Salmonella isolates in St Petersburg, Russia between 2002 and 2005 [34] . One MDR S. Virchow isolate contained a bla CTX-M-3 gene, and a second MDR S. Newport isolate contained an AmpC type bla CMY-2 . This is the first report of these enzymes in Salmonella in Russia. In a similar study of 13 692 isolates in Hungary, 14 Typhimurium and one Enteritidis isolates were ESBL producing [35] . ESBL enzymes detected included the first detection of bla CTX-M-5 (eight), bla CTX-M-15 (three) and bla SHV-5 (one) in Hungary.
Studies in the United States have previously found bla CMY-2 to be the principal gene responsible for extended spectrum cephalosporin resistance in salmonellae, particularly in S. Newport [36] . A more recent study conducted in the United States, focusing on Salmonella isolates, showed a wider range of enzymes [37] . Of the nontyphoidal salmonellae, 27 out of 14 043 (0.19%) isolates exhibited decreased susceptibility to quinolones and resistance to ESBLs (11 Seftenberg, six Typhimurium; three Newport; two Enteritidis; one each of Agona, Haifa, Mbandaka, Saintpaul and Uganda). Twenty-six isolates had a gyrA mutation, and all of 11 Seftenberg isolates also had a parC mutation. Resistance enzymes detected included qnrB2 (one), bla CMY-2 (eight), bla CMY-23 (one), bla SHV-12 (two), bla SHV-30 (one), bla OXA-1 (nine) and bla OXA-9 .
The spread of ESBL resistance genes in salmonellae in middle and low-income countries has also been recorded. In a surveillance network in Yucatan, Mexico, MDR bla CMY-2 S. Typhimurium increased from 0% (0 out of 27 isolates) in 2000-2001 to 75% (63 out of 84 isolates) in 2004-2005 [38 ] . The organism was isolated from sick children and retail meat or swine intestine. In a tertiary centre in Durban, South Africa, 41 salmonellae from children admitted to a paediatric ward were found to contain ESBL genes [39 ] . The most common serovars were Typhimurium (17) and Isangi (16) . SHV-12 was found in 39%, TEM-63 in 29% and TEM-116 in 10%. Other enzymes detected were TEM-131 (one), SHV-2 (two), CTX-M-3 (one), CTX-M-15 (two) and CTX-M-37 (five). In addition, CMY-2 (three) and OXA-1 were detected. This diversity of ESBL enzymes is a worrying development in a region with a high burden of invasive infection and limited ability to afford extended spectrum cephalosporin.
Treatment
A variety of studies have previously shown that the response to fluoroquinolones such as ciprofloxacin and ofloxacin is impaired in infections with S. Typhi isolates that are Na R with DCS [7] . Crump In-vitro studies have raised the suggestion that the new generation fluoroquinolone, gatifloxacin, may be more active than ciprofloxacin and ofloxacin, in isolates with DCS [9] . Two open randomized clinical trials have evaluated gatifloxacin in uncomplicated enteric fever. In a study in Kathmandu, Nepal, Pandit et al. [41 ] compared gatifloxacin (10 mg/kg once daily) with cefixime (20 mg/kg in two divided daily doses) in 390 randomized patients. The trial was stopped prematurely because of attainment of the a-priori defined trial endpoints. These studies provide further evidence for the value of azithromycin for treating uncomplicated enteric fever but raise concerns about the efficacy of cefixime in this role. They suggest that gatifloxacin is a potential new option in patients infected with isolates with DCS. However, gatifloxacin will not work against fully resistant strains now emerging in India. There are also reports of hyperglycaemia and hypoglycaemia associated with gatifloxacin, which appeared during the course of these trials, and have led to its withdrawal in a number of countries. In a population-based nested case-control study in Canadians aged 66 years and older, outpatient use of gatifloxacin, when compared with macrolide antibiotics, was associated with an increased risk of both hypoglycaemia (adjusted odds ratio, 4.3; 95% CI 2.9-6.3) and hyperglycaemia (adjusted odds ratio 16.7; 95% CI 10.4-26.8) [43] . In a further, retrospective, nested case-control study, the risk of hyperglycaemia increased in diabetic patients who received concomitant steroids or higher gatifloxacin doses than usually recommended by the manufacturer [44] . The risk of dysglycaemia has been found most commonly in elderly patients with underlying diseases rather than otherwise fit healthy children and adults who usually get enteric fever in endemic areas. A review of 867 children treated with gatifloxacin for acute otitis media showed an adverse events rate similar to the comparator antimicrobial (amoxicillin-clavulanate) and no specific problems with dysglycaemia [45] . Gatifloxacin should be avoided in elderly patients and those with diabetes, and in future trials, specific checks for dysglycaemia should be made so that the proven efficacy of the drug can be weighed against this potential adverse event.
Conclusion
Resistance to the commonly used antimicrobials in Salmonella is an important threat to public health. The patterns of resistance in the typhoidal and nontyphoidal salmonellae are constantly changing. The treatment of patients infected with MDR isolates with DCS is difficult, and nalidixic acid resistance is no longer a fully reliable method of detecting isolates with DCS. Although the occurrence of MDR S. Typhi and S. Paratyphi A has declined in many areas and isolates have remained susceptible to extended spectrum cephalosporin, full resistance to ciprofloxacin is now recorded in several centres in India. Resistance to ciprofloxacin and extended spectrum cephalosporins, in addition to the older antimicrobials in NTS serovars, will severely limit treatment options and lead to treatment failures [46] . Azithromycin and the carbapenems, such as imipenem, meropenem and ertapenem, are a potential reserve option in these circumstances [11, 42 ] . A recent report of a meropenem-resistant Salmonella isolate containing the carbapenemase, bla IMP-4 , as well as qnrB4, is therefore particularly worrying [47] . The emergence of resistance in S. Typhi should refocus attention on the value of vaccines as a public health intervention in endemic areas [48] [49] [50] . The World Health Organization has recently recommended the programmatic use of the licensed vaccines (Vi and Ty21a) for controlling endemic disease in specific areas where the burden of disease is great and antibiotic resistance rates high. Good surveillance mechanisms are needed to properly target these interventions, but these systems are frequently absent in high-burden endemic areas.
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